Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model

Background Hepatocellular carcinoma (HCC) larger than ten cm belonging to Barcelona Clinic Liver Cancer (BCLC) stage B and C may benefit from hepatic resection (HR), compared to presently recommended management by transarterial chemoembolization and sorafenib, respectively. This study reviews surviv...

Full description

Saved in:
Bibliographic Details
Published in:World journal of surgery 2015-06, Vol.39 (6), p.1510-1518
Main Authors: Chan, Yi-Chia, Kabiling, Catherine S., Pillai, Vinod G., Aguilar, Gustavo, Wang, Chih-Chi, Chen, Chao-Long
Format: Article
Language:English
Subjects:
Abdominal Surgery
Adult
Aged
Antineoplastic Agents - therapeutic use
Carcinoma, Hepatocellular - pathology
Carcinoma, Hepatocellular - therapy
Cardiac Surgery
Chemoembolization, Therapeutic
Female
General Surgery
Hepatectomy
Hepatic Resection
Humans
Liver Neoplasms - pathology
Liver Neoplasms - therapy
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Staging
Niacinamide - analogs & derivatives
Niacinamide - therapeutic use
Original Scientific Report
Overall Survival
Phenylurea Compounds - therapeutic use
Propensity Score
Retrospective Studies
Sorafenib
Surgery
Survival Rate
Tace
Thoracic Surgery
Tumor Burden
Vascular Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Hepatocellular carcinoma (HCC) larger than ten cm belonging to Barcelona Clinic Liver Cancer (BCLC) stage B and C may benefit from hepatic resection (HR), compared to presently recommended management by transarterial chemoembolization and sorafenib, respectively. This study reviews survival outcomes in such patients treated at a tertiary level hospital in Taiwan, and compares survival advantage of surgical resection over embolization therapy using a statistically valid propensity scores matching model. Methods 192 patients newly diagnosed with HCC ≥ 10 cm between 2005 and 2010, who had HR ( n  = 104) and transarterial embolization (TAE) ( n  = 88), were retrospectively studied. Thirty-two patients in each group were selected by propensity scores matching model for comparison. Results Survival rates at 1, 3, and 5 years of patients in BCLC stage B who had HR and TAE were 78.5, 61.4, 54.2 % and 30, 12.9, 12.9 %, ( p  
ISSN:0364-2313
1432-2323
DOI:10.1007/s00268-015-2975-y